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Abstract: Antibody-mediated rejection (AMR) has been identified as a significant form of acute allograft 
dysfunction in lung transplantation. The development of consensus diagnostic criteria has created a uniform 
definition of AMR; however, significant limitations of these criteria have been identified. Treatment 
modalities for AMR have been adapted from other areas of medicine and data on the effectiveness of 
these therapies in AMR are limited. AMR is often refractory to these therapies, and graft failure and death 
are common. AMR is associated with increased rates of chronic lung allograft dysfunction (CLAD) and 
poor long-term survival. In this review, we discuss the history of AMR and describe known mechanisms, 
application of the consensus diagnostic criteria, data for current treatment strategies, and long-term 
outcomes. In addition, we highlight current gaps in knowledge, ongoing research, and future directions 
to address these gaps. Promising diagnostic techniques are actively being investigated that may allow for 
early detection and treatment of AMR. We conclude that further investigation is required to identify and 
define chronic and subclinical AMR, and head-to-head comparisons of currently used treatment protocols 
are necessary to identify an optimal treatment approach. Gaps in knowledge regarding the epidemiology, 
mechanisms, diagnosis, and treatment of AMR continue to exist and future research should focus on these 
aspects.
Keywords: Lung transplantation; graft rejection; allograft tolerance; acute lung injury; complement component; 
complement C4d; diagnostic techniques and procedures; plasmapheresis; intravenous immunoglobulins (IVIG); 
rituximab; eculizumab; outcome assessment
Submitted Jul 21, 2019. Accepted for publication Nov 08, 2019.
doi: 10.21037/atm.2019.11.86
View this article at: http://dx.doi.org/10.21037/atm.2019.11.86
Introduction
Lung transplantation is the ultimate treatment for selected 
patients with end-stage lung disease. While advances in 
surgical technique have improved early survival, long 
term outcomes remain disappointing, and the median 
survival after transplantation in the most recent era is 
6.5 years (1). Chronic lung allograft dysfunction (CLAD) 
is the leading cause of death beyond the first year after 
lung transplantation and has emerged as the main barrier 
to better long-term outcomes (1). Antibody-mediated 
rejection (AMR) has been increasingly recognized after 
lung transplantation and has been consistently identified as 
a significant cause of morbidity, CLAD, and graft failure 
(2-7) .  Here,  we present  a  review of  our  current 
understanding of AMR and discuss ongoing research and 
future directions to further our understanding of AMR and 
improve the management of this serious complication after 
lung transplantation.
History
Our understanding of AMR in lung transplantation 
was historically limited to hyperacute rejection, which 
411
Review Article on Strategies to Achieve Long-Term Success of Lung Transplantation
Bery and Hachem. Pulmonary AMR
© Annals of Translational Medicine. All rights reserved.   Ann Transl Med 2020;8(6):411 | http://dx.doi.org/10.21037/atm.2019.11.86
Page 2 of 11
occurs when preformed donor-specific antibodies (DSA) 
bind to mismatched human leukocyte antigens (HLA) 
(8,9). Patients developed significant and often fatal 
graft failure intra-operatively or in the immediate post-
operative period with hemorrhagic pulmonary edema 
and diffuse pulmonary infiltrates on imaging studies 
(8,10,11). Severe graft dysfunction occurred in spite of 
intensive immunosuppression targeting T-cell proliferation 
and activity,  which suggested a role for humoral 
immunity in precipitating this response. Typically, these 
patients were found to have DSA and a positive direct 
lymphocytotoxicity crossmatch. Further investigation 
found that allosensitization was associated with worse 
survival after transplantation unless the reactive HLA were 
avoided in a prospective donor (8-10,12,13). Case reports of 
hyperacute rejection suggested the need for standardization 
of pretransplant crossmatching (6,8). Although hyperacute 
rejection has become rare in the current era because of 
improved HLA antibody detection assays, it illustrates that 
HLA antibodies can cause fulminant graft failure and that 
the capillary endothelium is the focal point of injury. 
Over time, cases occurring later after transplantation 
were recognized and our understanding of acute AMR 
began to evolve. Badesch and colleagues presented a case 
series of 5 patients with pulmonary capillaritis ranging 
from 3 weeks to months after transplant (14). In this 
series, all patients presented with alveolar hemorrhage 
and graft failure with temporary improvement in graft 
function with intensification of immunosuppression and 
plasmapheres is  (14) .  They postulated a  humoral 
immunologic response, though testing for DSA or 
antibody binding on pathologic specimens was not 
performed (14). Magro and colleagues described the 
histologic features of 22 lung transplant recipients who 
developed pulmonary capillaritis ranging from 1 to 33 
months after transplantation (15). They described septal 
capillary necrosis with staining positive for complement 
deposition (C1q, C3, and C4d) and immunoglobulin 
G (IgG) (15). All patients were tested and found to 
be negative for panel-reactive antibodies (PRA) both 
before transplantation and at the time of acute rejection; 
however, the use of older and less sensitive assays limits 
the significance of this finding (11,15). Treatment with 
plasmapheresis showed improvement in graft function and 
a decrease in post-pheresis capillary injury and complement 
deposition (15). Witt and colleagues detailed a series of 21 
patients with acute AMR (3). In this series, all patients had 
clinical allograft dysfunction, DSA, histology of acute lung 
injury, and capillary endothelial C4d deposition (3). Six 
patients (29%) died of refractory AMR, while 15 survived 
to hospital discharge (3). One patient had a diagnosis of 
bronchiolitis obliterans syndrome (BOS) at AMR diagnosis, 
and 13 of the remaining 14 survivors developed CLAD 
during follow up (3). Overall 15/21 (71%) patients died 
during the study period and median survival after diagnosis 
of AMR was 593 days (3). These studies established 
the basis for further investigation of the diagnosis and 
management of acute AMR. 
Pathogenesis
Mechanisms of AMR were init ial ly elucidated by 
investigations in transplantation of other solid organs, 
especially in kidney transplantation (16,17). This work has 
shown hyperacute, acute, and chronic forms of AMR in 
which activation of allospecific B-cells and plasma cells leads 
to formation of DSA that bind to HLA on the endothelium 
of vessels within the allograft (6,16,18,19). Antibody 
biding leads to complement dependent and independent 
recruitment of immune cells leading to graft dysfunction 
and tissue injury (6,16,18-20). 
DSA were first identified in renal transplant recipients 
in the 1960s and were postulated to be the underlying 
cause for immediate graft failure. Subsequent investigation 
confirmed that the presence of preformed antibodies 
in recipient sera was associated with a high rate of graft 
failure. These failures led to the use of a crossmatch of the 
recipients serum with donor cells and assays to identify 
DSA (21-23). Since that time, highly sensitive and specific 
solid phase assays for the identification of HLA antibodies 
have been developed (6,16,24). Recipients may have pre-
existing HLA antibodies (as a result of prior sensitizing 
events such as blood transfusion, pregnancy, or previous 
organ transplantation) or may develop HLA antibodies de 
novo after transplantation (6,9,11,12,17). Recipients may 
have antibodies to MHC class I antigens (HLA-A, HLA-B, 
or HLA-C) which are present on all nucleated cells, or to 
MHC class II antigens (HLA-DQ, HLA-DR, HLA-DP) 
which are present on antigen presenting cells (APCs) (25). 
Notably, pro-inflammatory cytokines have been shown 
to induce the expression of class II HLA on pulmonary 
endothelial cells (26,27). Recipients may also develop 
antibodies to non-HLA antigens (allo- or auto-antigens); 
however, no highly sensitive assays have been developed to 
detect such antibodies to date (5,25,28). 
Complement-binding DSA are associated with worse 
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outcomes in kidney and heart transplant recipients, 
and preliminary work echoes these findings in lung 
transplantation (3,29,30). DSA bind antigens on donor 
endothelial cells with activation of the classical complement 
cascade and formation of the membrane attack complex 
(MAC). The MAC causes endothelial cell injury with 
exposure of the basement membrane and activation of the 
coagulation cascade leading to thrombosis and infarction. 
Moreover, complement factors 3a and 5a (C3a and C5a) 
are chemokines that attract immune cells to the allograft 
propagating inflammation and graft injury (11,15,31). 
Importantly, not all DSA bind and activate complement, and 
DSA-associated complement-independent mechanisms of 
allograft injury have been studied in vitro and in vivo models 
of solid organ transplantation (6,16,31-36). Proposed 
mechanisms include activation of signaling cascades that 
lead to endothelial and smooth muscle cell proliferation, 
release of inflammatory cytokines and chemokines, and 
von Willebrand factor (vWF) and P-selectin mediated 
platelet activation (6,11,31-36). These findings not only 
implicate DSA in complement-independent mechanisms of 
AMR, but also suggest a role for DSA in chronic allograft 
rejection (6,11,31,36,37). 
Recent work by Li and colleagues has shown that 
the immunopathology of AMR may be different in 
lung allografts compared to allografts of other solid 
organs (38). This group utilized a mouse lung re-
transplantation model and found that tolerant pulmonary 
allografts developed bronchus-associated lymphoid tissue 
(BALT) (38). Suppression of FoxP3+ regulatory T-cells 
in this model led to the absence of BALT formation 
and development of AMR (38). These findings suggest 
that regulatory T-cells residing in BALT of pulmonary 
allografts suppress B-cell activation locally and that antigen 
presentation can occur within the allograft (38). These 
findings are contrary to models of AMR in other solid 
organ transplants where humoral responses are regulated 
peripherally (38). This is further echoed by the differences 
noted in the diagnosis, management, and outcomes of 
AMR in lung allografts as compared to other solid organ 
transplants (3-6,31,39,40). 
Clinical manifestations and diagnosis
The In terna t iona l  Soc ie ty  for  Hear t  and  Lung 
Transplantation (ISHLT) convened a working group in 
2016 to create a uniform definition of AMR (6). The 
definition was largely based on experience in kidney 
and heart transplantation. According to this definition, 
a definite diagnosis of AMR requires the presence of 
allograft dysfunction, DSA, characteristic lung pathology, 
complement factor 4d (C4d) deposition on capillary 
endothelium, and the exclusion of alternate etiologies 
of graft dysfunction (6). The working group recognized 
potential shortcomings of these diagnostic criteria and 
proposed a qualitative assessment of the certainty of the 
diagnosis as being definite, probable, or possible based 
on the number of criteria met (6). Graft dysfunction 
associated with clinical AMR may range from fulminant 
respiratory failure to asymptomatic dysfunction identified 
on surveillance spirometry (6). Chronic AMR is a defined 
form of rejection in kidney transplantation and has been 
suggested in both heart and lung transplantation, but 
there is no specific definition in lung transplantation 
(16,17). Although investigations in lung transplantation 
have shown an association between DSA and CLAD, 
which most commonly presents as BOS, it is unclear 
if  such cases represent chronic AMR as these are 
typically indistinguishable from cases that lack DSA 
(2-4,6,9,11,37,39,41). Furthermore, depletion of DSA has 
been associated with greater freedom from BOS (37). Roux 
and colleagues reviewed 206 transplanted patients and found 
that restrictive allograft syndrome (RAS) was only present 
in patients who had DSA and developed AMR, while BOS 
or mixed CLAD (BOS and RAS) were found in all groups 
of patients regardless of presence of DSA or AMR (5). It 
is appealing to consider whether RAS is a form of chronic 
AMR, but definitive data have been lacking to date. The 
ISHLT working group also recognized sub-clinical AMR as 
the detection of histologic criteria of AMR in the absence 
of graft dysfunction (6). Chronic and sub-clinical AMR 
remain poorly described in lung transplantation and further 
investigation is required to identify the significance of these 
diagnoses. 
The presence of DSA is requisite for a diagnosis of 
AMR based on these criteria; however, only a minority 
of patients with DSA go on to develop AMR (11,16,42). 
Furthermore, detection of DSA can be missed due to phasic 
release or absence of the antigen on the screening assay (6). 
Highly sensitive solid phase assays for DSA provide mean 
fluorescence intensity (MFI) values which do not always 
accurately depict antibody strength (43). Specificity can be 
improved with assays for binding of complement factor 1q 
(C1q) but this may decrease sensitivity (43). 
Multiple pathologic findings of AMR have been 
descr ibed  in  lung  a l logra f t s  inc lud ing  cap i l l a ry 
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inflammation, endothelialitis, and acute lung injury 
(9,44,45). The earliest report of hyperacute AMR of a 
lung allograft noted the presence of acute lung injury 
with hyaline membrane formation along with alveolar 
edema and hemorrhage (8). Subsequent reports described 
pulmonary capillaritis and neutrophilic infiltration as the 
hallmark findings of pulmonary AMR (46). However, 
further investigation has shown that neutrophils are just 
one of the many cell types that are part of the spectrum of 
microvascular inflammation and the absence of neutrophil 
infiltration or capillaritis should not rule out AMR 
(31,47,48). Neutrophilic capillaritis is nonspecific and has 
been associated with graft dysfunction in the absence of 
AMR (41,42,48). Furthermore, the presence of capillaritis 
may be obscured by severe acute lung injury. Acute lung 
injury may present as alveolar edema, alveolar hemorrhage, 
hyaline membrane formation with diffuse alveolar damage, 
fibrin deposition, intravascular platelet or fibrin thrombi, 
or arteriolar fibrinoid necrosis (2,47,49). These findings 
suggest that the histopathologic findings of AMR are 
nonspecific and underscore the need for a multidisciplinary 
approach to diagnosis.
Staining for complement split product C4d is the most 
controversial criterion for the diagnosis of AMR (50). 
Complement split products bind to endothelial cells non-
covalently and are subsequently inactivated by membrane 
cofactor protein, decay accelerating factor, and CD59 (51). 
However, unlike other complement split products, C4d 
binds the endothelium covalently via a thioester bond (51). 
This covalent bond is stable, resistant to shedding, and 
allows C4d to be detected long after other complement 
split products have been inactivated (51). While C4d 
staining gained popularity in diagnosis of AMR in renal 
allografts and provides direct evidence of the immune-
pathologic effect of antibodies, it has proven to be a 
challenging criterion in AMR of lung transplant recipients 
(5,6,11,44). C4d staining has been shown to be positive in 
pathology other than AMR such as ischemia-reperfusion 
injury, high grade ACR, and infection (5,6). Furthermore, 
C4d has been shown to be positive in only a minority of 
cases of AMR in lung transplant recipients, giving rise to 
“C4d-negative” AMR (2-4,52). It remains unclear if C4d-
negative AMR represents a unique form of AMR due to 
complement-independent pathways or if this is related to 
limitations of staining or interpretation of specimens (52). 
Finally, Roden and colleagues found poor correlation 
between immunofluorescence and immunohistochemical 
testing for C4d, and poor inter-reader reliability among 
pathologists (50). 
Treatment
Treatment options for AMR in lung transplantation 
have been adapted from other areas of medicine. Data 
supporting the use of individual interventions are sparse and 
no randomized clinical trials or head-to-head comparisons 
have been undertaken, making it difficult to draw 
conclusions about the efficacy of any single intervention 
(Table 1). Treatment regimens generally consist of multiple 
interventions and are individualized based on clinical course 
and response to other therapies. 
Corticosteroids
Corticosteroids inhibit the early steps of the acute 
inflammatory response by altering the transcription of 
numerous genes in leukocytes (53). These genes affect 
leukocyte maturation, differentiation, distribution, and 
trafficking (53). High-dose corticosteroids are utilized in 
treatment regimens for AMR across kidney, heart, and lung 
transplantation (4,16,54). Astor and colleagues presented 
a retrospective review of 40 patients of whom only 43% 
responded to steroid monotherapy (46). Steroid resistance 
was identified as a marker for AMR in early reports (14,46). 
Plasmapheresis
Plasmapheresis separates and discards plasma from whole 
blood replacing it with fresh frozen plasma or albumin and, 
therefore, eliminates circulating antibodies. In addition to 
reducing DSA, plasmapheresis has been shown to decrease 
deposition of complement split products (15). While 
plasmapheresis depletes circulating antibody, it does not 
decrease antibody production and can result in a rebound 
increase in antibody production. Due to its ability to eliminate 
circulating antibody, plasmapheresis gained popularity 
for the treatment of AMR in kidney transplantation (55). 
Retrospective studies in AMR of lung allografts have 
found variable benefit with use of plasmapheresis 
(4,7,8,10,12,14,15,46,56). These results are challenging to 
interpret, as plasmapheresis is rarely used as monotherapy and 
plasmapheresis protocols differ among studies. 
Intravenous immunoglobulin (IVIG)
IVIG has traditionally been used in the treatment of 
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immunodeficiency syndromes and passive immunity but 
also has applications in immune mediated conditions such as 
Guillan-Barré syndrome, immune thrombocytopenia (ITP), 
and myasthenia gravis. IVIG has become a standard part of 
protocols for treatment of AMR, but the precise mechanism 
of action is unclear (57). Proposed mechanisms include 
modulation of expression and function of the Fcγ receptor, 
inactivation of DSA, downregulation of B-cells, inhibition 
of the complement cascade and the cytokine network, and 
reduction of MHC class II antigen expression (57,58). IVIG 
may be used as monotherapy but is more commonly used 
in conjunction with plasmapheresis and/or corticosteroids 
(57,59). Dosing of IVIG has been variable with ranges from 
100–2,000 mg/kg (4,57). 
Rituximab
Rituximab is an anti-CD20 antibody that binds to pre-
B-cells and mature B-lymphocytes in circulation, lymph 
nodes, and bone marrow and induces apoptosis and cell 
lysis (60). While rituximab depletes circulating B-cells, 
it has no known effect on plasma cells that may already 
be producing antibody. Rituximab has been studied in 
the treatment of B-cell neoplasms and autoimmune 
conditions (60). Rituximab plus IVIG was found to improve 
survival over IVIG alone in a protocol to preemptively 
treat DSA; however, groups were not randomized and no 
difference in rejection rates was found (37). Indeed, data for 
the treatment of AMR with rituximab are sparse. 
Proteasome inhibition
Proteasomes degrade misfolded and ubiquitinated proteins. 
Bortezomib and carfilzomib bind and inhibit proteasomes 
in plasma cells allowing the accumulation of these proteins 
and leading to plasma cell apoptosis (61-63). Proteasome 
inhibitors have largely been studied in the treatment of 
multiple myeloma (61,62). Observational studies have 
shown that treatment with proteasome inhibitors in AMR 
depletes DSA and improves allograft function (61,62), but 
no head-to-head comparisons or clinical trials have been 
published to date. 
Complement inhibition
Eculizumab is a monoclonal antibody that binds to C5 and 
inhibits formation of the MAC. Eculizumab has largely 
been studied in atypical hemolytic uremic syndrome. 
Case reports utilizing eculizumab as part of a multimodal 
treatment regimen for AMR have shown depletion of DSA 
and improvement in allograft function (10,64), but no head-
to-head comparisons or clinical trials have been published 
to date.
Long-term outcomes
Despite improvements in diagnosis, clinical outcomes after 
AMR remain poor (39). Astor and colleagues reported 
a case series of 40 patients who developed AMR and 
found 1- and 5-year survival to be near 80% and 40% 
respectively (46). Otani and colleagues presented a series 
of 9 patients who received therapy for AMR in which 
5/9 initially improved with therapy, but 7/9 eventually 
developed CLAD and 6/9 (67%) died within 3 years of 
diagnosis of AMR (4). Witt and colleagues reported a series 
Table 1 Treatment modalities for AMR in lung transplantation
Treatment Mechanism References
Corticosteroids Alter transcription of genes in leukocytes (4,14,16,46,53,54)





Unclear; proposed mechanisms include modulation of Fcγ receptor, 
inactivation of DSA, downregulation of B-cells, inhibition of 
complement cascade, reduction of MHC class II expression
(4,57-59)
Rituximab Depletion of circulating B-cells (37,60)
Proteasome Inhibition Plasma cell apoptosis (61-63)
Complement Inhibition Inhibition of formation of the membrane attack complex (10,64)
AMR, antibody-mediated rejection; DSA, donor-specific antibodies.
Bery and Hachem. Pulmonary AMR
© Annals of Translational Medicine. All rights reserved.   Ann Transl Med 2020;8(6):411 | http://dx.doi.org/10.21037/atm.2019.11.86
Page 6 of 11
of 21 patients who developed AMR of whom 6/21 died 
of refractory AMR, and all 15 who improved eventually 
developed CLAD (3). Overall, 15/21 (71%) patients died 
during the study period and the median survival after the 
diagnosis of AMR was 593 days (3). Aguilar and colleagues 
reported a series of 73 cases of AMR and found a 30-day 
mortality of 26% despite aggressive antibody depleting 
treatment (52). Indeed, multiple reports have shown that 
the inability to clear DSA and a diagnosis of AMR are 
associated with increased risk of CLAD (3,4). These reports 
suggest that although AMR may be a reversible cause of 
acute graft dysfunction, there is a high incidence of CLAD 
and poor long-term survival after AMR. 
Sensitization prior to transplantation
The presence of HLA antibodies prior to transplantation 
has been associated with variable outcomes. While some 
reports found no difference in survival, acute rejection, or 
BOS, others have shown decreased survival, decreased rates 
of transplantation, prolonged waiting times, and increases 
in post-transplant ventilator days, acute rejection, AMR, 
and BOS (65-70). Notably, HLA class II antibodies have 
been associated with worse outcomes (3,52,68). Brugiere 
and colleagues found that patients with class II DSA had 
significantly higher mortality and significantly lower 
freedom from BOS (68). Descriptive studies by Witt et al. 
and Aguilar et al. also noted an association between HLA 
class II antibodies, especially HLA-DQ antibodies, and the 
development of AMR (3,52). Notably, pro-inflammatory 
cytokines have been shown to induce the expression of class 
II HLA on pulmonary endothelial cells (26,27). Together, 
these studies illustrate that endothelial cells are the focal 
point of antibody-mediated injury. 
Desensitization protocols have been implemented 
for sensitized patients with variable success. Appel and 
colleagues treated 12/35 (34%) sensitized patients with 
peri-transplant IVIG and extracorporeal immunoadsorption 
(ECI) and found a significant decrease in acute rejection 
but no significant difference in survival or BOS (71). Snyder 
and colleagues treated 18/114 (16%) sensitized patients 
with a desensitization protocol including plasmapheresis, 
methylprednisolone,  bortezomib,  r i tuximab,  and 
IVIG (72). Among the 9/18 (50%) treated patients who 
went on to receive a transplant, they found a significant 
decrease in HLA antibody with pretreatment MFI 
5,000–10,000; however, they found no difference in 
PRA, cPRA, or post-transplant survival (72). Tinckam 
and colleagues treated 146 patients with known DSA or 
with PRA >30% with a desensitization protocol including 
perioperative plasma exchange, IVIG, anti-thymocyte 
globulin, and mycophenolic acid and compared them to 
194 unsensitized controls (73). They found that treated, 
sensitized recipients had significantly lower rates of acute 
rejection compared with unsensitized controls and found 
no significant difference in spirometry or 1-year graft 
survival (73). Courtwright and colleagues reviewed 203 
cases, 18 of whom had pretransplant DSA and were treated 
with peri-transplant plasmapheresis, and found that 
sensitized patients were more likely to require prolonged 
mechanical ventilation and to have AMR (74). They found 
no difference in mortality or CLAD-free survival between 
groups (74). While some centers have shown success, small 
sample size, varied protocols and immunosuppressive 
regimens, and heterogenous patient populations make it 
challenging to draw conclusions regarding the role and 
impact of desensitization protocols. 
Gaps in knowledge and future directions
Despite the advances in diagnostic criteria and treatment 
modalities in AMR, significant gaps in knowledge 
remain. The true incidence of AMR remains unknown 
with prior reports describing widely variable incidence 
from 4% to greater than 50% (3,37,75,76). The previous 
lack of consensus diagnostic criteria and highly sensitive 
assays for DSA may explain this variability. However, the 
limitations of the current consensus diagnostic criteria 
present further challenges in defining the true incidence 
of AMR. In addition, chronic and subclinical AMR are ill-
defined, and the impact of these potential forms of rejection 
on long-term outcomes remains unknown. The lack of 
highly sensitive assays for non-HLA antibodies further 
limits our understanding of AMR. While inability to clear 
DSA is associated with CLAD and poor survival, the 
associated mechanisms remain unclear, and protocols for 
prevention and treatment have yet to be developed. Long-
term outcomes after AMR are poor and data for specific 
treatment protocols remain sparse. Large, multicenter, 
randomized clinical trials are necessary to better define 
the optimal treatment regimen. These studies need not 
be placebo controlled as equipoise exists for head-to-head 
comparisons of previously studied regimens. Furthermore, 
dosing studies are necessary to identify the optimal doses 
for treatment of AMR as current dosing strategies are 
based on the use of agents in other medical conditions. 
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Finally, as investigations of new diagnostic techniques and 
treatment strategies emerge, large, multicenter studies will 
be necessary to identify best-practices for implementation. 
There are multiple areas of ongoing and future 
investigation in AMR including in the areas of mechanisms, 
diagnosis, and treatment. Li and colleagues developed 
a mouse lung re-transplantation model of AMR and 
found that tolerant allografts developed BALT and that 
depletion of regulatory T-cells led to AMR (38). They 
suggest a role for future investigation of the pathogenesis 
of AMR utilizing this model and the treatment of AMR by 
costimulatory blockade of T-cells and B-cells (38). 
Given the limitations of the current consensus diagnostic 
criteria for AMR, alternative methods for diagnosis are 
actively being investigated including donor-derived cell-free 
DNA (ddcfDNA) and transcriptome analyses. The presence 
of injury in the allograft results in donor cell apoptosis and 
circulation of donor DNA in the serum of recipients (77-80). 
Assays have been developed that can quantify the amount 
of ddcfDNA in recipient serum (77-81). This technique 
involves sequencing DNA found in the serum of recipients 
and differentiating and quantifying donor DNA (77,81). 
These assays were found to have excellent sensitivity for 
acute rejection, but specificity is poor (77-81). Notably, 
Agbor-Enoh and colleagues found the sensitivity for AMR 
to be approaching 100%, but specificity was only 35%; 
however, when coupled with testing for DSA, specificity 
improved to 90% (82,83). In addition, they found that 
elevations in ddcfDNA preceded the clinical diagnosis of 
AMR by a median of 2.8 months (82). Measurement of cell-
free DNA could serve as a noninvasive method to diagnose 
impending AMR; however, it is unclear if treatment of 
impending AMR will improve outcomes. The Early 
Detection and Treatment of AMR (eDATA) study proposes 
to identify patients who have elevated ddcfDNA and 
DSA and to initiate treatment prior to developing clinical 
AMR. This study is currently in progress and will compare 
outcomes with conventional diagnosis and treatment of 
clinical AMR (83). 
Another area of active investigation is transcriptome 
analysis. Micro RNAs (miRNA) are short, noncoding RNA 
sequences that regulate gene expression. Transcriptome 
analysis can be performed on BAL cell pellets, peripheral 
blood mononuclear cells, and biopsy specimens (84-88). 
Early studies have shown that differential expression of 
miRNAs correlate with episodes of acute rejection and 
may even precede diagnosis of chronic rejection (84-88). 
While early data for antibody associated chronic rejection 
exists (84), transcriptome analysis has yet to be evaluated in 
the diagnosis of AMR.
Valenzuela and colleagues reviewed emerging therapies 
for AMR that inhibit antibody formation and antibody-
mediated allograft injury by targeting CTLA4, IL-6 
receptor, B-cell activating factor, C1, mTOR, and the 
Fc region of bound antibody (40). Future studies should 
evaluate the role of these alternate pathways of immune 
modulation in AMR.
Conclusions
AMR generally results in severe acute allograft dysfunction 
and is associated with increased risk of CLAD and poor 
survival. Despite development of consensus diagnostic 
criteria, treatment protocols have limited data and long-
term outcomes remain poor. Promising diagnostic 
techniques are actively being investigated that may allow 
for early detection and treatment of AMR. Further research 
is required to identify and define chronic and subclinical 
AMR, and head-to-head comparisons of currently used 
treatment protocols are necessary to identify an optimal 
treatment approach. Gaps in knowledge regarding the 
epidemiology, mechanisms, diagnosis, and treatment of 
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